AR023219A1 - Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s) - Google Patents
Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s)Info
- Publication number
- AR023219A1 AR023219A1 ARP000101440A ARP000101440A AR023219A1 AR 023219 A1 AR023219 A1 AR 023219A1 AR P000101440 A ARP000101440 A AR P000101440A AR P000101440 A ARP000101440 A AR P000101440A AR 023219 A1 AR023219 A1 AR 023219A1
- Authority
- AR
- Argentina
- Prior art keywords
- synthase
- thiol
- combination
- groups
- involved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La presente se refiere a una composicion farmacéutica que contienen, en calidad de ingrediente activo, una o más sustancias que interfieren en la síntesisdel monoxido de nitrogeno mediante la inhibicion de la NO-sintasa y uno o más antioxidantes metabolicos que poseen por lo menos dos grupo tiol y queintervienen en el status de la redox de grupos tiol, y opcionalmente un soporte farmacéuticamente aceptable. Se refiere también a un producto que contiene unao más sustancias inhibidoras de la NO sintasa y uno o muchos antioxidantes metabolicos que poseen por lo menos dos grupos tiol que intervienen en el status dela redox de grupo tiol, en forma de un producto de combinacion, en forma separada, de estos ingredientes activos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9904134A FR2791571B1 (fr) | 1999-04-02 | 1999-04-02 | Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023219A1 true AR023219A1 (es) | 2002-09-04 |
Family
ID=9543945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000101440A AR023219A1 (es) | 1999-04-02 | 2000-03-30 | Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1169005A2 (es) |
JP (1) | JP2002541077A (es) |
AR (1) | AR023219A1 (es) |
AU (1) | AU3663700A (es) |
CA (1) | CA2365500A1 (es) |
FR (1) | FR2791571B1 (es) |
MY (1) | MY133230A (es) |
NO (1) | NO20014770L (es) |
WO (1) | WO2000059448A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2816509B1 (fr) * | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene |
US6476073B1 (en) * | 2000-11-21 | 2002-11-05 | Arthur Vanmoor | Method of treating a hangover by enhancing the effectiveness of the human immune system |
WO2004073623A2 (en) * | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
DE602005012089D1 (de) | 2005-08-04 | 2009-02-12 | Extarma Ag | Flüssige Zusammensetzung enthaltend Arginine und alpha-Liponsäure zur Verbesserung der sexuellen Funktion |
WO2009111037A2 (en) * | 2008-03-04 | 2009-09-11 | Indigene Pharmaceuticals Inc. | Compositions and methods for treating nos-associated diseases |
JP2011521908A (ja) * | 2008-05-09 | 2011-07-28 | デューク ユニバーシティ | チオレドキシンが細胞における一酸化窒素放出を調節するという知見に基づく疾患の治療法 |
TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
US20150025147A1 (en) * | 2012-03-02 | 2015-01-22 | Kyowa Hakko Bio Co., Ltd | Enhancer for eating activity and/or gastrointestinal activity |
JP6509112B2 (ja) * | 2012-07-03 | 2019-05-08 | プラブダ,ジェイ | オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4630M (es) * | 1965-06-09 | 1966-11-28 | ||
ZA716628B (en) * | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
US5091180A (en) * | 1987-11-20 | 1992-02-25 | Administrators Of The Tulane Educational Fund | Protection against rhabdomyolysis-induced nephrotoxicity |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US5852058A (en) * | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
GB9404400D0 (en) * | 1994-03-07 | 1994-04-20 | Wood Pauline J | Potentiation of bioreductive agents |
DE4420102A1 (de) * | 1994-06-09 | 1995-12-14 | Asta Medica Ag | Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen |
AU5317296A (en) * | 1995-03-24 | 1996-10-16 | Francis V. Defeudis | Methods for treating conditions associated with excess nitri c oxide |
US5951990A (en) * | 1995-05-15 | 1999-09-14 | Avon Products, Inc. | Ascorbyl-phosphoryl-cholesterol |
EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
AU8768098A (en) * | 1997-08-04 | 1999-02-22 | Christopher J. Berry | Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof |
AU759467B2 (en) * | 1998-04-02 | 2003-04-17 | Avicena Group, Inc. | Compositions containing a combination of a creatine compound and a second agent |
-
1999
- 1999-04-02 FR FR9904134A patent/FR2791571B1/fr not_active Expired - Lifetime
-
2000
- 2000-03-29 MY MYPI20001265A patent/MY133230A/en unknown
- 2000-03-30 AR ARP000101440A patent/AR023219A1/es unknown
- 2000-03-31 CA CA002365500A patent/CA2365500A1/fr not_active Abandoned
- 2000-03-31 AU AU36637/00A patent/AU3663700A/en not_active Abandoned
- 2000-03-31 JP JP2000609013A patent/JP2002541077A/ja active Pending
- 2000-03-31 WO PCT/FR2000/000812 patent/WO2000059448A2/fr active Search and Examination
- 2000-03-31 EP EP00915262A patent/EP1169005A2/fr not_active Withdrawn
-
2001
- 2001-10-01 NO NO20014770A patent/NO20014770L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FR2791571B1 (fr) | 2002-10-04 |
CA2365500A1 (fr) | 2000-10-12 |
WO2000059448A2 (fr) | 2000-10-12 |
FR2791571A1 (fr) | 2000-10-06 |
MY133230A (en) | 2007-10-31 |
EP1169005A2 (fr) | 2002-01-09 |
NO20014770D0 (no) | 2001-10-01 |
AU3663700A (en) | 2000-10-23 |
WO2000059448A3 (fr) | 2001-03-08 |
JP2002541077A (ja) | 2002-12-03 |
NO20014770L (no) | 2001-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007013065A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
BR0113661A (pt) | Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2 | |
GB0114286D0 (en) | Nucleoside Derivatives | |
WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
UA94065C2 (en) | Dihydropseudoerythromycin derivatives | |
WO2006102610A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
MX2007001553A (es) | Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados. | |
MEP39108A (en) | Pharmaceutical composition | |
TW200738280A (en) | Novel pharmaceutical compositions comprising levetiracetam and process for their preparation | |
WO2007028022A3 (en) | Novel compounds as p2x7 modulators and uses thereof | |
HK1110787A1 (en) | Pharmaceutical composition comprising glutathione compounds and betalain for the prevention and treatment of cancer | |
ATE485261T1 (de) | Salicylsäurederivate | |
AR023219A1 (es) | Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s) | |
TW200621773A (en) | Bicyclononene derivatives | |
BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas | |
AR035875A1 (es) | Composicion farmaceutica estable de inhibidores de reductasa hmg-coa, y una tableta para la administracion oral | |
MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
BRPI0408848A (pt) | formulações orais de cladribine | |
TW200724145A (en) | Substituted acrylamide derivatives and pharmaceutical compositions thereof | |
IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
WO2004069145A3 (en) | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them | |
DE69815100D1 (de) | Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten | |
BRPI0520821A2 (pt) | formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada | |
TW200621774A (en) | Bicyclononene derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |